, ,
This is an online portal with information on donations that were announced publicly (or have been shared with permission) that were of interest to Vipul Naik. The git repository with the code for this portal, as well as all the underlying data, is available on GitHub. All payment amounts are in current United States dollars (USD). The repository of donations is being seeded with an initial collation by Issa Rice as well as continued contributions from him (see his commits and the contract work page listing all financially compensated contributions to the site) but all responsibility for errors and inaccuracies belongs to Vipul Naik. Current data is preliminary and has not been completely vetted and normalized; if sharing a link to this site or any page on this site, please include the caveat that the data is preliminary (if you want to share without including caveats, please check with Vipul Naik). We expect to have completed the first round of development by the end of July 2025. See the about page for more details. Also of interest: pageview data on analytics.vipulnaik.com, tutorial in README, request for feedback to EA Forum.
Item | Value |
---|---|
Country | |
Facebook page | ScrippsResearchInstitute |
Website | http://www.scripps.edu |
Twitter username | scrippsresearch |
Wikipedia page | https://en.wikipedia.org/wiki/Scripps_Research_Institute |
Cause area | Count | Median | Mean | Minimum | 10th percentile | 20th percentile | 30th percentile | 40th percentile | 50th percentile | 60th percentile | 70th percentile | 80th percentile | 90th percentile | Maximum |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Overall | 16 | 864,700 | 2,133,524 | -2,254,000 | 263,357 | 316,096 | 327,377 | 710,300 | 864,700 | 2,351,662 | 3,000,000 | 3,342,614 | 4,997,674 | 12,066,128 |
Global health | 16 | 864,700 | 2,133,524 | -2,254,000 | 263,357 | 316,096 | 327,377 | 710,300 | 864,700 | 2,351,662 | 3,000,000 | 3,342,614 | 4,997,674 | 12,066,128 |
Donor | Total | 2018 | 2017 | 2016 | 2015 | 2014 |
---|---|---|---|---|---|---|
Bill and Melinda Gates Foundation (filter this donee) | 34,136,389.23 | -1,599,246.00 | 18,928,644.23 | 3,378,058.00 | 10,428,933.00 | 3,000,000.00 |
Total | 34,136,389.23 | -1,599,246.00 | 18,928,644.23 | 3,378,058.00 | 10,428,933.00 | 3,000,000.00 |
There are no documents associated with this donee.
Graph of top 10 donors (for donations with known year of donation) by amount, showing the timeframe of donations
Donor | Amount (current USD) | Amount rank (out of 16) | Donation date | Cause area | URL | Influencer | Notes |
---|---|---|---|---|---|---|---|
Bill and Melinda Gates Foundation | 327,377.00 | 11 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support the discovery and early development of novel therapeutic agents against cryptosporidiosis and malaria; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 327,377.00 | 11 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to support the discovery and early development of novel therapeutic agents against cryptosporidiosis and malaria; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | -2,254,000.00 | 16 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support late preclinical and early clinical development of a novel treatment for cryptosporidiosis; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 2,993,188.00 | 6 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to fund the development of cell therapies/vaccines to enable long-term antibody based immunity to HIV and other normally antibody resistant pathogens of global concern for which no effective vaccines exists; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 12,066,128.23 | 1 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to make progress towards influenza and malaria vaccines that will be of great benefit for global health; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 3,342,614.00 | 4 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support late preclinical and early clinical development of a novel treatment for cryptosporidiosis; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 263,357.00 | 14 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support the discovery and early development of novel therapeutic agents against cryptosporidiosis and malaria; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 263,357.00 | 14 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to support the discovery and early development of novel therapeutic agents against cryptosporidiosis and malaria; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 2,351,662.00 | 7 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support late preclinical and early clinical development of a novel treatment for cryptosporidiosis; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 316,096.00 | 13 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to define the molecular signature of effective germinal center dynamics in order to optimize timing, antigen format and memory T cell help in ways that can be rapidly utilized to assess effective vaccine strategies; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 710,300.00 | 10 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | To support general operating costs for work on structure-based immunogen design of a Pfs25 transmission-blocking vaccine for falciparum malaria; Aid type: Core support to NGOs, other private bodies, PPPs and research institutes. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 4,997,674.00 | 2 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to evaluate the feasibility of passive protection using a novel entry inhibitor, eCD4-Ig, to prevent HIV-1 infection; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 864,700.00 | 9 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to provide general operating support. Gen Ops Support - GC: Preventing HIV-1 transmission with a novel entry inhibitor, eCD4-Ig. Investment start date: 9/16/2015 to end date: 7/31/2020. Grantee name: The Scripps Research Institute; Aid type: Core support to NGOs, other private bodies, PPPs and research institutes. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 1,015,629.00 | 8 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to provide general operating support to TSRI to support a variety of scientific research and purchase of a Titan Krios electron microscope will be used to solve cryo-EM structures of HIV-1 immunogens to guide rational vaccine design efforts; Aid type: Core support to NGOs, other private bodies, PPPs and research institutes. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 3,550,930.00 | 3 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to accelerate HIV-1 vaccine research to help identify the best vaccine candidates for HIV-1 eradication; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 3,000,000.00 | 5 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to provide general operating support to TSRI to support a variety of scientific research and purchase of a Titan Krios electron microscope will be used to solve cryo-EM structures of HIV-1 immunogens to guide rational vaccine design efforts; Aid type: Core support to NGOs, other private bodies, PPPs and research institutes. Affected regions: Developing countries, unspecified. |